Drug Topics

JANUARY 19, 2024

Problematic substance use was highest among firefighters, followed by emergency medical technicians, and police officers.

220

220

Pharmacy Times

JANUARY 19, 2024

Benzodiazepines have proven effective in managing anxiety and insomnia, but they heighten risk of falls, cognitive impairment, functional decline, and mortality among older adults.

156

156

STAT

JANUARY 19, 2024

Scientists at Dana-Farber Cancer Institute, one of the nation’s leading cancer research and treatment centers, are “moving to” retract one paper and correct others amid an expanding investigation of data manipulation, officials told STAT. The investigation includes scores of papers authored by four top scientists and institute leaders, including CEO Laurie Glimcher and COO William Hahn.

Hospitals 145

Hospitals 145

Pharmacy Times

JANUARY 19, 2024

The third edition of the Pharmacy Quality Alliance resource guide includes 40 total SDOH services and 8 new services, as well as 10 initiative updates from the previous 2 editions.

149

149

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

JANUARY 19, 2024

A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.

144

144

STAT

JANUARY 19, 2024

WASHINGTON — Theranos founder and ex-CEO Elizabeth Holmes is banned from federal health programs for nine decades, the health department announced Friday. Holmes was sentenced in November 2022 to 11 years in prison following a trial that determined she knew her blood-testing startup, which was founded in 2003 and which claimed to be able to test for a range of diseases and risks with one finger prick, produced inaccurate and faulty results.

142

142

Drug Topics

JANUARY 19, 2024

Findings from the current study lend scientific credence to the idea that making informed dietary choices can help promote favorable health outcomes.

123

123

Pharmacy Times

JANUARY 19, 2024

The treatment is for patients with KRAS G12C-mutant metastatic NSCLC who have previously received at least 1 systemic therapy and were not treated with a KRAS G12C inhibitor.

FDA 123

FDA 123

Fierce Pharma

JANUARY 19, 2024

Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021.

Vaccines 128

Vaccines 128

STAT

JANUARY 19, 2024

Hospitals aren’t usually in the business of selling technology tools. But that’s changing thanks to a collision of financial pressures and an explosion of new technology that could both improve patients’ health and ease the burden of administrative tasks on limited staff. At the J.P. Morgan Healthcare conference, an exclusive, invitation-only event for investors, several influential health systems like Mayo Clinic and Mass General Brigham doubled down on new revenue streams

Hospitals 126

Hospitals Mayo Clinic 126

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Pharma

JANUARY 19, 2024

More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnose | More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients.

FDA 128

FDA 128

STAT

JANUARY 19, 2024

The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about a best-selling breast cancer treatment in a television ad in 2022. In a letter dated Thursday, the agency admonished the company for touting the benefits of its Kisqali medicine by referencing data that did not support the messages in the ad. In particular, the FDA cited an analysis of patient-reported outcomes data that had limitations and failed to demonstrate Kisqali “helps preserve

FDA 123

FDA 123

Fierce Healthcare

JANUARY 19, 2024

Lightfully Behavioral Health, a hybrid mental health provider, has launched a new offering to support college students. | Lightfully U is intended to support the more than 60% of college students who have at least one mental health condition. The offering is a virtual intensive outpatient program targeted at college students ages 18 through 25 with higher-acuity conditions.

122

122

Drug Topics

JANUARY 19, 2024

According to IQVIA's most recent Global Use of Medicine report, losses for originator products are projected to rise by over $80 billion over the next 5 years due to market introductions of new biosimilar and generic drugs.

98

98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

JANUARY 19, 2024

Intermountain Health plans to shut down Saltzer Health, a multispecialty group the system acquired less than four years ago, if it’s unable to find a buyer by March 29, according to an announcement | Saltzer Health has more than 450 employees across 11 Idaho locations. It attributes its situation to "significant financial pressures," but said it is "optimistic" that at least some services could be sold to a new owner.

118

118

Fierce Pharma

JANUARY 19, 2024

A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence in the disease area with a wo | The drug bolsters the company's portfolio in paroxysmal nocturnal haemoglobinuria (PNH) just as the market heats up thanks to new competitors from Novartis and Apellis.

118

118

Fierce Healthcare

JANUARY 19, 2024

UnitedHealthcare is rolling out a new resource hub that seeks to make it easier for members to use wellness offerings while also easing the financial burden on employers. | UnitedHealthcare is rolling out a new resource hub that seeks to make it easier for members to use wellness offerings while also easing the financial burden on employers.

117

117

Pharmacy Times

JANUARY 19, 2024

In 2024, there is an urgent need for policies that will accelerate biosimilar use to achieve lower system-wide health care costs.

132

132

Fierce Healthcare

JANUARY 19, 2024

Traditional Medicare’s bar for reimbursing long-term care hospitals (LTCH) for severely ill, “high-cost outlier” patients has spiked under current payment policies. | The cutoff for an expensive long-term care hospital case to qualify for greater reimbursement rose 55% from FY 2023 to FY 2024, and is projected to rise another 17% the following year, AHA wrote in a recent white paper calling for policymaker intervention.

Hospitals 115

Hospitals 115

Pharmacy Times

JANUARY 19, 2024

Hospital pharmacists can play an important role in advocating for, designing, and implementing various policies to optimize care.

Hospitals 131

Hospitals 131

Drug Store News

JANUARY 19, 2024

Cara McNulty, president, behavioral health and mental well-being, CVS Health, discusses the resources CVS Health has implemented to prevent suicides as well as programs to help people before or during a mental health crisis.

115

115

pharmaphorum

JANUARY 19, 2024

Learn more about Graham Heap, Takeda VP and the lead of TAK-279, in this exclusive live interview at JP Morgan in 2024. Gain insights into Heap's role, achievements, and the future of TAK-279.

114

114

STAT

JANUARY 19, 2024

What a week — this year’s might have been the busiest JPM I’ve ever had. I’m not saying that to brag, it’s a statement about the industry. There was even one tweet from STAT’s Adam Feuerstein calling the meeting mood “jubilant.” As a partner at an executive search firm, I’d concur. My time was packed with the usual mix of requests from potential, current, and former clients as well as investors to discuss search projects, and of cour

108

108

The Checkup by Singlecare

JANUARY 19, 2024

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted the state of Florida the authority to import certain prescription drugs from Canada—an important measure to counteract soaring prescription costs. It is the first time the FDA has authorized a state to import prescription medications from another country, which sets the precedent for more states and Indian tribes to follow suit.

FDA 105

FDA Dosage Insurance 105

pharmaphorum

JANUARY 19, 2024

Basel, Switzerland, is becoming an innovative biotech hub at the forefront of the digital revolution, proving fertile ground for a variety of start-ups in the healthcare space.

105

105

STAT

JANUARY 19, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. We’re seeing some rays of hope that this ghastly biotech job market may loosen up a bit. Also, Bernie Sanders wants to subpoena some pharma CEOs, and as always, we’ve got a rad podcast for you today.

96

96

pharmaphorum

JANUARY 19, 2024

Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101. The drug – a new dry powder intranasal formulation of the well-established migraine therapy dihydroergotamine mesylate (DHE) – was submitted for approval in the US last March as an easy-to-use, portable treatment option for acute migraine attacks, with or without aura, in adult patients.

FDA 104

FDA 104

European Pharmaceutical Review

JANUARY 19, 2024

According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. Currently in Phase I development , the antibiotic’s novel mechanism of action was showcased through its effectiveness against the pathogen in in vitro studies.

Hospitals 95

Hospitals 95

pharmaphorum

JANUARY 19, 2024

AstraZeneca gets its first approval for oral Factor D inhibitor danicopan, in Japan, for treatment of paroxysmal nocturnal haemoglobinuria

115

115

European Pharmaceutical Review

JANUARY 19, 2024

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations. An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable,

Chemotherapy 89

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Labelling 89

pharmaphorum

JANUARY 19, 2024

CG Oncology joins the queue of US biotech companies hoping to complete an IPO, aiming to raise $181m for its late-stage bladder cancer therapy.

110

110

Pharmacy Times

JANUARY 19, 2024

Protecting this vulnerable patient population requires specially designed strategies.

Hospitals 121

Hospitals 121

STAT

JANUARY 19, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.   That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

86

86

Drug Store News

JANUARY 19, 2024

Nutrabolt will take an ownership stake of approximately 20% in Bloom Nutrition, which is part of a larger $90 million financing.

103

103